Last edition
News about "Yusri Elsayed"
J&J's RYBREVANT Plus Chemotherapy Delivers Nearly 3-Year Survival in EGFR Exon 20 NSCLC
J&J’s RYBREVANT (amivantamab) plus chemotherapy delivers a median Overall Survival of 34.3 months in EGFR exon 20 insertion mutation-positive Non-Small Cell Lung Cancer (NSCLC).
Yusri Elsayed | 14/09/2026 | By News Bureau
Johnson & Johnson's RYBREVANT FASPRO Gets US FDA Priority Review for Advanced Head and Neck Cancer
Johnson & Johnson's RYBREVANT FASPRO has received US Food and Drug Administration (FDA) Priority Review (PR) as a potential first-in-class subcutaneous treatment for advanced head and neck cancer.
Yusri Elsayed | 01/08/2026 | By News Bureau | 140
Johnson & Johnson Secures US FDA Priority Review for TAR-200 NDA
Johnson & Johnson has announced that the US FDA has granted Priority Review to its New Drug Application for TAR-200, a first-of-its-kind intravesical gemcitabine-releasing system, for treating BCG-unresponsive high-risk non-muscle invasive bladder cancer with carcinoma in situ.
Yusri Elsayed | 18/07/2025 | By Mrinmoy Dey | 199
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy